Barclays PLC increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 31.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,872 shares of the company's stock after acquiring an additional 24,010 shares during the quarter. Barclays PLC owned about 0.18% of Harmony Biosciences worth $3,471,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also added to or reduced their stakes in HRMY. FMR LLC boosted its stake in shares of Harmony Biosciences by 1.9% during the 4th quarter. FMR LLC now owns 5,329,902 shares of the company's stock valued at $183,402,000 after purchasing an additional 101,182 shares in the last quarter. Vanguard Group Inc. boosted its position in Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after acquiring an additional 1,262,362 shares in the last quarter. Pacer Advisors Inc. grew its holdings in shares of Harmony Biosciences by 18.2% during the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock worth $78,452,000 after acquiring an additional 351,582 shares during the period. American Century Companies Inc. raised its position in shares of Harmony Biosciences by 28.7% in the 4th quarter. American Century Companies Inc. now owns 1,102,604 shares of the company's stock worth $37,941,000 after acquiring an additional 246,140 shares in the last quarter. Finally, LSV Asset Management lifted its stake in shares of Harmony Biosciences by 23.8% in the 4th quarter. LSV Asset Management now owns 956,217 shares of the company's stock valued at $32,903,000 after purchasing an additional 184,026 shares during the period. Institutional investors own 86.23% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on HRMY. HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. Needham & Company LLC reissued a "buy" rating and set a $50.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Mizuho upped their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price target on the stock. Finally, UBS Group reduced their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday, April 28th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences has a consensus rating of "Buy" and an average target price of $52.44.
Read Our Latest Stock Report on Harmony Biosciences
Harmony Biosciences Stock Up 1.5 %
HRMY traded up $0.46 during trading on Friday, hitting $30.32. 857,912 shares of the company's stock traded hands, compared to its average volume of 574,597. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of 14.37, a PEG ratio of 0.47 and a beta of 0.80. The company's 50 day simple moving average is $31.41 and its two-hundred day simple moving average is $34.08. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.
Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. The company had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. During the same period last year, the company earned $0.45 EPS. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.
Harmony Biosciences Profile
(
Free Report)
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Recommended Stories

Before you consider Harmony Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harmony Biosciences wasn't on the list.
While Harmony Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.